Abstract
The vascular endothelium expresses differential receptors depending on the functional state and tissue localization of its cells. A method to characterize this receptor heterogeneity with phage display random peptide libraries has been developed. Using this technology, several peptide ligands have been isolated that home to tissue-specific endothelial cell receptors following intravenous administration. Such peptide ligands, or antibodies directed against specific vascular receptors, can be used to target therapeutic compounds or imaging agents to endothelial cells
in vitro and
in vivo. Recent advances in the field include identification of novel endothelial receptors expressed differentially in normal and pathological conditions and the isolation of peptides or antibody ligands to such receptors in
in vitro assays, in animal models and in a human patient. These milestones, which extend the ‘functional map’ of the vasculature, should lead to clinical applications in diseases such as cancer and other conditions that exhibit distinct vascular characteristics.
There have been important recent advances in characterizing vascular heterogeneity and in targeting specific vascular receptors
in vitro and
in vivo. Clinical trials to test targeted compounds are needed to translate this strategy into useful clinical applications.